



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

4<sup>th</sup> February, 2023

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir / Madam,

Please find enclosed herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref: PR/17/2022-23**

**4<sup>th</sup> February, 2023**

### **USFDA COMPLETES INSPECTION OF NATCO'S VIZAG FORMULATION FACILITY**

***Hyderabad, India, February 4<sup>th</sup>, 2023***

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to announce the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA) for its Formulation facility in Ramky SEZ, near Visakhapatnam (Vizag), India, which was conducted during the period 30<sup>th</sup> January, 2023 to 3<sup>rd</sup> February, 2023.

At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure. The Company is confident of addressing all observations within the stipulated time.

---

For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer